Deferasirox in Indian children with thalassemia major: 3 years experience

Objective: To evaluate the efficacy and safety of the oral iron chelator deferasirox in treating transfusional hemosiderosis in a cohort of Indian children with thalassemia major with high iron load. Materials and Methods: The first 50 children (age 2-18 yrs) with thalassemia major to commence defer...

Full description

Bibliographic Details
Published in:	Indian Journal of Medical and Paediatric Oncology
Main Authors:	Mayank Dhamija, Amita Mahajan, Manas Kalra, Anju Virmani
Format:	Article
Language:	English
Published:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2013-01-01
Subjects:	Deferasirox serum ferritin thalassemia major
Online Access:	http://www.ijmpo.org/article.asp?issn=0971-5851;year=2013;volume=34;issue=1;spage=16;epage=20;aulast=Dhamija

Similar Items

Comparison of deferasirox and deferoxamine effects on iron overload and immunological changes in patients with blood transfusion-dependent β-thalassemia
by: Hayder M Al-Kuraishy, et al.
Published: (2017-01-01)

Comparison of the Mean Serum Ferritin Levels in Thalassaemia Major Patients after Giving Deferasirox and Deferoxamine
by: Seema Aftab, et al.
Published: (2017-12-01)

Investigating the Effect of Iron Chelation Therapy With Deferasirox on Liver Aminotransferases Levels in Transfusion-dependent β-thalassemia Patients
by: Shayan Pourkazem, et al.
Published: (2024-06-01)

Renal function in patients with thalassemia major receiving Exjade® dispersible tablets and a new film-coated tablet formulation of deferasirox (Nanojade®)
by: Vahid Falahati, et al.
Published: (2022-01-01)

DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA
by: Ali Taher
Published: (2018-11-01)

THE ANTIOXIDANT EFFECTS OF CAPPARIS OVATA AND DEFERASIROX IN PATIENTS WITH THALASSEMIA MAJOR
by: Handan Duman, et al.
Published: (2014-08-01)

Combination iron chelation therapy with deferiprone and deferasirox in iron-overloaded patients with transfusiondependent β-thalassemia major
by: Hossein Karami, et al.
Published: (2017-01-01)

Comparison of the effects of deferasirox film-coated tablets (Jadenu®) and deferasirox dispersible tablets (Exjade®) in patients with beta thalassemia major: a preliminary report of the effects on the satisfaction, convenience, cardiac/liver MRI T2*, serum ferritin level, and biochemical profiles
by: Mahya Mobinikhaledi, et al.
Published: (2024-11-01)

JADENU® SUBSTITUTING EXJADE® IN IRON OVERLOADED Β- THALASSEMIA MAJOR (BTM) PATIENTS: A PRELIMINARY REPORT OF THE EFFECTS ON THE TOLERABILITY, SERUM FERRITIN LEVEL, LIVER IRON CONCENTRATION AND BIOCHEMICAL PROFILES
by: Vincenzo De Sanctis
Published: (2018-10-01)

THE RELATION BETWEEN TYPES OF IRON CHELATORS AND FERITIN ON OSTEOCALCIN OF THALASSEMIA PATIENTS WITH REPEATED TRANSFUSIONS
by: Sesa Amelia, et al.
Published: (2020-01-01)

Two trade names of deferasirox (Osveral® and Exjade®) in reduction of iron overload parameters in major beta-thalassemia patients: A randomized open labeled clinical trial
by: Mohammadreza Rafati, et al.
Published: (2022-01-01)

Study of Significance of Echocardiography and Estimation of Serum Ferritin Levels in Beta-thalassemia Major Patients
by: Shahana Khanum, et al.
Published: (2023-10-01)

Hematological Parameters in Beta Thalassemia Major Children
by: Zamzam Mohamed, et al.
Published: (2022-04-01)

Association of Serum Ferritin Levels with Haematological Parameters in Thalassaemia Major Patients
by: Amna Faruqi
Published: (2014-12-01)

Use of Deferasirox Film-Coated Tablets in Pediatric Patients with Transfusion Dependent Thalassemia: A Single Center Experience
by: Alkistis Adramerina, et al.
Published: (2022-02-01)

LONG-TERM EFFECTIVENESS, SAFETY, AND TOLERABILITY OF TWICE-DAILY DOSING WITH DEFERASIROX IN CHILDREN WITH TRANSFUSION-DEPENDENT THALASSEMIAS UNRESPONSIVE TO STANDARD ONCE-DAILY DOSING
by: Jassada Buaboonnam, et al.
Published: (2021-10-01)

Efficacy and safety of deferasirox in pediatric patients of thalassemia at a Tertiary Care Teaching Hospital
by: Dhaval R Thakor, et al.
Published: (2017-01-01)

Lens opacity as a serious side effect following chelation therapy in beta thalassemia: A comparison between deferoxamine and deferasirox; randomized double-blinded clinical trial
by: Mohammad Reza Golpayegani, et al.
Published: (2019-01-01)

Correlation of Increased Serum Ferritin with SGOT, SGPT, and Albumin Levels in Children with β-Thalassemia Major
by: Cut Nanda Feby Ayulinda, et al.
Published: (2022-11-01)

The COST-UTILITY ANALYSIS OF FOUR CHELATION REGIMENS FOR Β-THALASSEMIA MAJOR: A CHINESE PERSPECTIVE
by: Jialian Li
Published: (2020-04-01)

High Prevalence of Hypoparathyroidism in Patients with beta-Thalassemia Major
by: Amir Ali Hamidieh, et al.
Published: (2009-07-01)

High Prevalence of Hypoparathyroidism in Patients with beta-Thalassemia Major
by: Amir Ali Hamidieh, et al.
Published: (2009-09-01)

Bilateral Nuclear Cataract with Deferasirox in a Patient of Beta-thalassemia: A Case Report and Literature Review
by: Tushit Dhar, et al.
Published: (2024-04-01)

Effective method of evaluating myocardial iron concentration in pediatric patients with thalassemia major
by: Khaled A, et al.
Published: (2019-07-01)

ECONOMIC EVALUATION OF CHELATION REGIMENS FOR β--THALASSEMIA MAJOR: A SYSTEMATIC REVIEW
by: Jialian Li
Published: (2019-06-01)

Assessing the auditory effects of oral chelation therapy drug Deferasirox in individuals with β‐thalassemia major
by: Balwinder S. Tiwana, et al.
Published: (2024-12-01)

Duodenal perforation caused by deferasirox “case report”
by: Mohammmed Al Blooshi, et al.
Published: (2023-07-01)

Stable Luminescent Poly(Allylaminehydrochloride)-Templated Copper Nanoclusters for Selectively Turn-Off Sensing of Deferasirox in β-Thalassemia Plasma
by: Hung-Ju Lin, et al.
Published: (2021-12-01)

A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan
by: Wan-Ling Ho, et al.
Published: (2013-04-01)

Serum Lipids in Turkish Patients with β-Thalassemia Major and β-Thalassemia Minor
by: Yasemin Işık Balcı, et al.
Published: (2016-02-01)

Growth and endocrinopathies among children with β-Thalassemia major treated at Dubai Thalassemia centre
by: Rabah Almahmoud, et al.
Published: (2024-04-01)

Body Iron Status and Its Complications in Patients With Beta Thalassemia Major: A Cross-Sectional Study
by: Shafaq Ismail, et al.
Published: (2023-11-01)

IRON CHELATION THERAPY IN THALASSEMIA SYNDROMES
by: Paolo Cianciulli
Published: (2009-06-01)

Evaluation of Vitamin D level in thalassemia patients: The experience of a single center
by: Alaa M Al-Rubae, et al.
Published: (2023-01-01)

Comparison of Efficacy, Safety, and Humanistic Outcomes of Iron-Chelation Therapy in Pediatrics Suffering from Transfusion-Dependent β-Thalassemia Major
by: Narayana Goruntla, et al.
Published: (2020-07-01)

Growth Failure in β-Thalassemia major Patients Undergoing Repeated Transfusions
by: Shazia Ali , Sarwat Jahan
Published: (2016-09-01)

Prevalence of Candida albicans in the oral cavity of Beta Thalassemia Major and Thalassemia Minor Patients [version 2; peer review: 2 approved]
by: Maha Adel Mahmood, et al.
Published: (2025-08-01)

Prevalence of Candida albicans in the oral cavity of Beta Thalassemia Major and Thalassemia Minor Patients [version 1; peer review: 2 approved]
by: Maha Adel Mahmood, et al.
Published: (2025-06-01)

Clinical Manifestations of β-Thalassemia Major in Two Different Altitudes; Bushehr and Shahrekord
by: Mohammad Reza Ravanbod, et al.
Published: (2016-04-01)

The Corellation Between Serum Ferritin and Cardiac Troponin I in Major Beta Thalassemia Children
by: Muhammad Ali Shodikin, et al.
Published: (2016-04-01)